Effect of sivelestat sodium in patients with acute lung injury or acute respiratory distress syndrome: a meta-analysis of randomized controlled trials

Shenglan Pu, Daoxin Wang, Daishun Liu, Yan Zhao, Di Qi, Jing He and Guoqi Zhou

Abstract

Background: Sivelestat is widely used in treating acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), although the clinical efficacy of sivelestat remains controversial. This study aimed to evaluate the impact of sivelestat in patients with ALI/ARDS.

Methods: Electronic databases, PubMed, Embase, and the Cochrane Library, were searched to identify trials through April 2017. Randomized controlled trials (RCTs) were included irrespective of blinding or language that compared patients with and without sivelestat therapy in ALI/ARDS. A random-effects model was used to process the data, and the relative risk (RR) and standard mean difference (SMD) with corresponding 95% confidence intervals (CIs) were used to evaluate the effect of sivelestat.

Results: Six RCTs reporting data on 804 patients with ALI/ARDS were included. Overall, no significant difference was found between sivelestat and control for the risk of 28–30 days mortality (RR: 0.94; 95% CI: 0.71–1.23; P = 0.718). Sivelestat therapy had no significant effect on ventilation days (SMD: 0.05; 95% CI: −0.27 to 0.38; P = 0.748), arterial oxygen partial pressure (PaO2)/fractional inspired oxygen (FiO2) level (SMD: 0.48; 95% CI: −0.45 to 1.41; P = 0.315), and intensive care unit (ICU) stays (SMD: −9.87; 95% CI: −24.30 to 4.56; P = 0.180). The results of sensitivity analysis indicated that sivelestat therapy might affect the PaO2/FiO2 level in patients with ALI/ARDS (SMD: 0.87; 95% CI: 0.39 to 1.35; P < 0.001).

Conclusions: Sivelestat therapy might increase the PaO2/FiO2 level, while it had little or no effect on 28–30 days mortality, ventilation days, and ICU stays. These findings need to be verified in large-scale trials.

Keywords: Sivelestat sodium, Patients, Acute lung injury, Acute respiratory distress syndrome
sivelestat in clinical needs is yet to be interpreted. Several randomized controlled trials (RCTs) have indicated that sivelestat therapy can improve ventilation days and arterial oxygen partial pressure (PaO2)/fractional inspired oxygen (FiO2), while the efficacy of sivelestat therapy on other outcomes in patients with ALI/ARDS remains controversial. Therefore, a systematic review and meta-analysis of available RCTs were conducted to evaluate the treatment effect of sivelestat.

**Methods**

**Data sources, search strategy, and selection criteria**

This review was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis Statement issued in 2009 (Additional file 1: Checklist S1) [13].

A systematic review and meta-analysis of RCTs published through April 2017 were conducted to identify trials of sivelestat for patients with ALI/ARDS. Electronic databases PubMed, Embase, and the Cochrane Library were searched using the following key words: (“sivelestat” OR “elaspol”) AND (“ARDS” OR “adult respiratory distress syndrome” OR “acute respiratory distress syndrome” OR “noncardiogenic pulmonary edema” OR “respiratory insufficiency” OR “systemic inflammatory response syndrome” OR “shock lung” OR “respiratory failure” OR “lung injury” OR “septic shock” OR “sepsis”). Manual searches of the reference lists were also conducted from all relevant original and review articles to identify additional eligible studies. No language restriction was applied. Unpublished trials were excluded. The medical subject heading, methods, patient disease status, study design, intervention, and outcome variables were used to identify relevant studies.

The literature search was independently performed by two authors using a standardized approach. Any inconsistencies were settled by a group discussion until a consensus was reached. The included studies met the following criteria. (1) RCTs, (2) patients confirmed with ALI/ARDS, (3) patients received sivelestat, and (4) data included 28–30 days mortality, improved ventilation days, PaO2/FiO2 level, and intensive care unit (ICU) stays. All retrospective clinical studies that could affect the treatment effects due to various confounding biases were excluded.

The ethical approval and written consent are not necessary for the meta-analysis, because the data of meta-analysis is collected from published literature.

**Data collection and quality assessment**

The data collected included the first author’s name, publication year, country, sample size, mean age, percentage of male, disease status, intervention, baseline PaO2/FiO2 ratio, baseline acute physiology and chronic health evaluation (APACHE II) score, reported endpoints, and study design variables. The authors independently scanned the titles and abstracts of the studies for eligibility and relevance. Potentially relevant articles were retrieved and reviewed for selection based on the inclusion and exclusion criteria. Any discrepancies were resolved by discussion. Further, the Jadad scale was employed to evaluate the methodological quality, based on randomization, concealment of treatment allocation, blinding, completeness of follow-up, and use of intention-to-treat analysis [14].

**Statistical analysis**

Relative risks (RRs) and standard mean differences (SMDs) with 95% confidence intervals (CIs) were calculated using outcomes extracted from each study before data pooling. The random-effects model was used to calculate pooled RRs with 95% CI to estimate the effect of sivelestat on the risk of 28–30 days mortality, and SMDs were employed to estimate the efficacy of sivelestat therapy on the ventilation days, PaO2/FiO2 level, and ICU stays [15, 16]. Heterogeneity among trials was investigated using the Q statistic, and P values <0.10 were indicative of significant heterogeneity [17, 18]. Sensitivity analyses were conducted for ventilation days and PaO2/FiO2 level by removing each individual study from the meta-analysis [19]. The subgroup analysis was also performed for 28–30 days mortality based on publication year, mean age, percentage of male, disease status, baseline PaO2/FiO2 ratio, and Jadad score. The visual inspection of funnel plots for 28–30 days mortality was conducted. The Egger [20] and Begg [21] tests were also used to statistically assess the publication bias for 28–30 days mortality. All reported P values were two sided, and P values <0.05 were considered as statistically significant. Statistical analyses were performed using the STATA software (version 10.0; Stata Corporation, TX, USA).

**Results**

The results of the study-selection process are shown in Fig. 1. A total of 541 potentially relevant articles were identified after systematically searching electronic databases, professional journals, and other sources. After reviewing the titles or abstracts, 527 were excluded as they did not meet the inclusion criteria, leaving 14 articles for further full-text reviews. Six RCTs were finally identified and included for the analysis of treatment effect of sivelestat in patients with ALI/ARDS [22–27], and the rest were excluded for the following reasons: conference abstracts without full text, retrospective study, and no desirable outcomes. A manual search of the reference lists of these trials did not yield any new eligible studies. The general characteristics of the included studies are presented in Table 1.
Six RCTs involving a total of 804 patients with ALI/ARDS were included. The mean age of the patients was 56.0–73.1 years. Each trial included 22–487 individuals. Further, the percentage of included males ranged from 59.3%–76.0%. Five trials were conducted in Japan [22–25, 27], and the remaining one trial in multiple countries [26]. Four of the included trials reported patients with ALI [22, 24, 26, 27], one trial included patients with ARDS [25], and the remaining one trial included patients with both ALI and ARDS [23]. Moreover, five trials included patients who received 0.2 mg/kg/h sivelestat [22–25, 27], and one trial included those who received 0.16 mg/kg/h sivelestat [26]. The study quality was assessed using the Jadad score and is presented in Table 1. Overall, four trials had a score of 3 [22, 24, 26, 27], and the remaining two had a score of 2 [23, 25].

All included trials reported the effect of sivelestat on the risk of 28–30 days mortality. The summary results indicated no significant difference between sivelestat and control for the risk of 28–30 days mortality (RR: 0.94; 95% CI: 0.71–1.23; \( P = 0.643 \); Fig. 2), and without evidence of heterogeneity. The sensitivity analysis found that the risk of 28–30 days mortality was reduced by 42%, but was not statistically significant when excluding the study by Zeiher et al. (RR: 0.58; 95% CI: 0.29–1.18; \( P = 0.131 \); Fig. 2). This trial specifically included a higher incidence of mortality within 28–30 days and included patients who received low-dose sivelestat therapy.

A total of five trials reported the effect of sivelestat therapy on ventilation days in patients with ALI/ARDS. No significant difference was found between sivelestat and control for ventilation days (SMD: 0.05; 95% CI: −0.27 to 0.38; \( P = 0.748 \); Fig. 3). Although substantial heterogeneity was observed in the magnitude of the effect across the studies (\( P = 0.028 \)), the conclusion was not affected by the exclusion of any specific study after the sequential exclusion of each study from all of the pooled analyses (Table 2).

A total of four trials reported the effect of sivelestat therapy on PaO\(_2\)/FiO\(_2\) in patients with ALI/ARDS. It was noted that the PaO\(_2\)/FiO\(_2\) level in patients with ALI/ARDS who received sivelestat therapy had increased by 0.48, although it was not statistically significant (SMD: 0.48; 95% CI: −0.45 to 1.41; \( P = 0.315 \); Fig. 4), and the potential evidence of significant heterogeneity was detected (\( P < 0.001 \)). According to the sensitivity analysis, the study by Tamakuma et al. was excluded because it specifically included patients with higher baseline PaO\(_2\)/FiO\(_2\) level and might affect the treatment effect of sivelestat therapy. After this exclusion, it was concluded that sivelestat therapy significantly increased the level of
Table 1 Baseline characteristic of studies included in the systematic review and meta-analysis

| Study     | Publication year | Country  | Sample size | Mean age | Percentage male (%) | Disease status | Intervention                          | Baseline PaO2/FiO2 ratio | Baseline APACHE II score | Jadad scale |
|-----------|------------------|----------|-------------|----------|---------------------|----------------|----------------------------------------|-------------------------|--------------------------|-------------|
| Endo [22] | 2006             | Japan    | 26          | NA       | NA                  | ALI            | 0.2 mg/kg/h for 14 days                | NA                      | NA                       | 3           |
| Sato [23] | 2008             | Japan    | 24          | 69.0     | 75.0                | ALI/ARDS       | 0.2 mg/kg/h for 14 days                | 196.5                   | NA                       | 2           |
| Morimoto [24] | 2011    | Japan    | 22          | 73.1     | 63.6                | ALI            | 0.2 mg/kg/h until weaning from mechanical ventilation | <150.0                  | NA                       | 3           |
| Kadoi [25] | 2004             | Japan    | 24          | 64.0     | 75.0                | ARDS           | 0.2 mg/kg/h for 14 days                | 148.5                   | 20.1                     | 2           |
| Zeiher [26] | 2004             | Multiple countries | 487        | 560      | 59.3                | ALI            | 0.16 mg/kg/h for 14 days               | 148.7                   | 20.8                     | 3           |
| Tamakuma [27] | 2004             | Japan    | 221         | 57.8     | 76.0                | ALI            | 0.2 mg/kg/h for 14 days                | 199.0                   | NA                       | 3           |

ALI: Acute lung injury, APACHE II: acute physiology and chronic health evaluation, ARDS: acute respiratory distress syndrome, FiO2: fractional inspired oxygen, PaO2: arterial oxygen partial pressure.


PaO_2/FiO_2 in patients with ALI/ARDS (SMD: 0.87; 95% CI: 0.39 to 1.35;  P < 0.001; Table 2). Moreover, sivelestat therapy had little or no effect on ICU stays in patients with ALI/ARDS (SMD: −9.87; 95% CI: −24.30 to 4.56;  P = 0.180; Fig. 5) (Table 3).

Fig. 2 Effect of sivelestat on the risk of 28–30 days mortality

The publication bias was assessed using the funnel plot for 28–30 days mortality (Fig. 6). Although the Begg test showed no evidence of publication bias for 28–30 days mortality, the Egger test showed potential evidence of publication bias. However, the results were not influenced after adjustment for publication bias using the trim-and-fill method [28].

**Discussion**

The objective of the present meta-analysis was to evaluate the effect of sivelestat therapy in patients with ALI/ARDS. Six trials including 804 patients with ALI/ARDS were included. The summary results showed that sivelestat therapy had little or no significant effect on 28–30 days mortality, ventilation days, PaO_2/FiO_2 level, and ICU stays.

Fig. 3 Effect of sivelestat therapy on ventilation days
The findings of the sensitivity analysis indicated that sivelestat therapy might play a beneficial effect on the level of PaO2/FiO2. These results might help better define the treatment effect of sivelestat therapy in patients with ALI/ARDS and help physicians to select appropriate treatment strategies.

A previous meta-analysis including eight trials suggested that sivelestat therapy was not associated with 28–30 days mortality and mechanical ventilation days, while it was associated with lower PaO2/FiO2 ratio in patients with ALI/ARDS [29]. The study did not recommend its routine use in patients with ALI/ARDS. The effect of sivelestat therapy on ICU stays was not conducted, and the treatment effects according to different baseline characteristics were not performed. Therefore, the present study conducted a comprehensive systematic review and meta-analysis to evaluate the effect of sivelestat therapy in patients with ALI/ARDS.

The findings of the present study suggested that sivelestat therapy had no significant effect on 28–30 days mortality. All included trials reported that sivelestat therapy did not affect the risk of mortality within 28–30 days. However, nearly all trials reported that the incidence of 28–30 days mortality reduced but was not statistically significant. Moreover, Zeiher et al. found that sivelestat therapy was associated with a nonsignificant increase in the risk of 28 days mortality by 2% [26]. The possible reason could be the efficacy of sivelestat on 28 days mortality which might be affected by specific clinical conditions [30]. Meanwhile, sivelestat has maximum efficacy in patients with mild to moderate ARDS [31]. Further, the treatment effects of sivelestat were correlated with age, disease status, haemodialysis, and methylprednisolone use [32]. Furthermore, subgroup analyses for 28 days mortality, excluding the study conducted by Zeiher et al., were performed [26].

---

**Table 2** Sensitivity analysis for ventilation days and PaO2/FiO2

| Outcomes       | Excluding study | SMD (95% CI)     | P value | Heterogeneity (%) | P value for heterogeneity |
|----------------|-----------------|------------------|---------|-------------------|--------------------------|
| Ventilation days | Sato            | −0.02 (−0.29 to 0.25) | 0.865   | 50.7              | 0.107                    |
|                | Morimoto        | 0.09 (−0.27 to 0.45)  | 0.633   | 71.4              | 0.015                    |
|                | Kadoi           | 0.14 (−0.17 to 0.45)  | 0.388   | 61.3              | 0.052                    |
|                | Zeiher          | 0.08 (−0.48 to 0.64)  | 0.766   | 65.4              | 0.034                    |
|                | Tamakuma        | −0.02 (−0.54 to 0.50)  | 0.950   | 62.9              | 0.044                    |
| PaO2/FiO2       | Morimoto        | 0.37 (−0.73 to 1.47)   | 0.507   | 97.4              | <0.001                   |
|                | Kadoi           | 0.53 (−0.58 to 1.64)   | 0.350   | 97.4              | <0.001                   |
|                | Zeiher          | 0.18 (−0.53 to 0.89)   | 0.623   | 73.2              | 0.024                    |
|                | Tamakuma        | 0.87 (0.39 to 1.35)    | <0.001  | 49.1              | 0.140                    |

CI confidence interval, FiO2 fractional inspired oxygen, PaO2 arterial oxygen partial pressure, SMD standard mean difference, RR relative risk

---

**Fig. 4** Effect of sivelestat therapy on PaO2/FiO2
findings of subgroup analysis were consistent with the overall analysis.

No significant difference was found between sivelestat therapy and control for ventilation days. Mostly included trials indicated that sivelestat therapy had no significant effect on ventilation days, while the trial conducted by Sato et al. reported inconsistent results [23]. This study specifically included patients with both ALI and ARDS, which might affect ventilation days. Further, the Sato's study might include more severe ALI/ARDS patients, which was associated with lower respiratory function so that sivelestat became less effective [33]. Finally, sivelestat therapy did not affect the PaO₂/FiO₂ level, and ICU stays in ALI/ARDS patients. However, these conclusions may be variable since a smaller number of trials were included. Therefore, the present study gave a relative result and provided a synthetic and comprehensive review.

The strengths of this meta-analysis were as follows: (1) the large sample size allowed the quantitative assessment of the efficacy of sivelestat, and thus these findings were

### Table 3 Subgroup analyses for 28–30 days mortality excluding the study conducted by Zeiher et al.

| Group                        | RR (95% CI) | P value | Heterogeneity (%) | P value for heterogeneity | P value for interaction test |
|------------------------------|-------------|---------|-------------------|---------------------------|-----------------------------|
| Publication year             |             |         |                   |                           |                             |
| 2005 or after                | 0.49 (0.16–1.52) | 0.215   | 0.0               | 0.992                     | 0.696                       |
| Before 2005                  | 0.65 (0.27–1.59) | 0.344   | 0.0               | 0.427                     |                             |
| Mean age (years)             |             |         |                   |                           |                             |
| ≥ 65.0                       | 0.53 (0.09–2.92) | 0.462   | 0.0               | 0.949                     | 0.897                       |
| < 65.0                       | 0.60 (0.28–1.28) | 0.186   | 0.0               | 0.677                     |                             |
| Percentage male (%)          |             |         |                   |                           |                             |
| ≥ 70.0                       | 0.63 (0.27–1.44) | 0.272   | 0.0               | 0.713                     | 0.741                       |
| < 70.0                       | 0.48 (0.13–1.79) | 0.277   | 0.0               | 0.898                     |                             |
| Disease status               |             |         |                   |                           |                             |
| ALI                          | 0.48 (0.20–1.15) | 0.100   | 0.0               | 0.992                     | 0.468                       |
| ALI/ARDS or ARDS             | 0.83 (0.25–2.71) | 0.757   | 0.0               | 0.611                     |                             |
| Baseline PaO₂/FiO₂ ratio     |             |         |                   |                           |                             |
| ≥ 150                        | 0.48 (0.17–1.37) | 0.170   | 0.0               | 0.975                     | 0.634                       |
| < 150                        | 0.68 (0.26–1.77) | 0.430   | 0.0               | 0.751                     |                             |
| Jadad score                  |             |         |                   |                           |                             |
| 3                            | 0.48 (0.20–1.15) | 0.100   | 0.0               | 0.992                     | 0.468                       |
| 2                            | 0.83 (0.25–2.71) | 0.757   | 0.0               | 0.611                     |                             |

ALI Acute lung injury, ARDS acute respiratory distress syndrome, CI confidence interval, FiO₂ fractional inspired oxygen, PaO₂ arterial oxygen partial pressure, RR relative risk
potentially more robust than any individual study. Second, the results of ICU stays were summarized, as the previous meta-analysis was not conducted. Third, the treatment effect of sivelestat in patients with ALI/ARDS according to different baseline characteristics was conducted, which provided any potential effect of sivelestat therapy in specific subpopulations.

The limitation of this study were as follows: (1) the number of included studies was smaller than expected, which always acquired broad CIs, that is, no statistically significant difference; (2) data on baseline APACHE score of the enrolled patients were available in two trials, which might affect the treatment effect of sivelestat in ALI/ARDS patients [25, 26]; (3) the information about ALI/ARDS classification were available in two trials [26, 27] and other trials could not provide diagnosis criteria of ALI/ARDS patients, which was correlated with the treatment effects of sivelestat; (4) mostly included trials were conducted in Japan, which might induce ethnic biases; (5) in a meta-analysis of published studies, publication bias is inevitable; and (6) the analysis used pooled data (individual data were not available), which prevented a detailed analysis to obtain more comprehensive results.

**Conclusion**

The findings of this study suggested that sivelestat therapy might play an important role on the PaO$_2$/FiO$_2$ level, while it had no significant effect on 28–30 days mortality, ventilation days, and ICU stays. Future large-scale trials should focus on different disease status, patient characteristics, and trials from other countries to analyze any possible efficacy and safety of sivelestat therapy.

**Additional file**

Additional file 1: Prisma 2009 Checklist. (DOC 72 kb)

**Abbreviations**

ALI: Acute lung injury; ARDS: Acute respiratory distress syndrome; CIs: Confidence intervals; FiO$_2$: Fractional inspired oxygen; ICU: Intensive care unit; PaO$_2$: Arterial oxygen partial pressure; RCTs: Randomized controlled trials; RR: Relative risk; SMD: Standard mean difference

**Acknowledgements**

None

**Funding**

None

**Availability of data and materials**

The dataset supporting the conclusions of this article is included within the article.

**Authors’ contributions**

SLP and DXW contributed to conception and design; SLP, DXW, DSL, YZ, DQ, JH and GQZ contributed to acquisition of data, or analysis and interpretation of data; SLP, DXW, DSL, YZ, DQ, JH and GQZ have been involved in drafting the manuscript or revising it critically for important intellectual content; all authors have given final approval of the version to be published.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
